Xenon Pharmaceuticals Analyst Ratings
BenzingaApr 12 07:02 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaApr 10 09:46 ET
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
TipRanksMar 5 01:35 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaMar 1 08:10 ET
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk
MT NewswiresMar 1 08:09 ET
Buy Rating Justified by Xenon Pharmaceuticals' Advanced Epilepsy Program and Growth Prospects in Neuroscience
TipRanksMar 1 02:45 ET
Maintaining Buy Rating on Xenon Pharmaceuticals With a $60 Target Amidst XEN1101 Clinical Advancements
TipRanksJan 8 18:45 ET
Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62
BenzingaJan 4 04:47 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaJan 4 04:46 ET
B of A Securities Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $56
BenzingaJan 2 10:48 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaJan 2 10:46 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaDec 18, 2023 10:56 ET
Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63
BenzingaDec 8, 2023 05:29 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaDec 8, 2023 05:27 ET
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56
BenzingaNov 28, 2023 04:31 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaNov 28, 2023 04:29 ET
Maintained Buy Rating on Xenon Pharmaceuticals: Promising Signals for XEN1101 Despite Trial Challenges
TipRanksNov 27, 2023 18:15 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaNov 9, 2023 10:44 ET
Xenon Pharmaceuticals Analyst Ratings
BenzingaOct 24, 2023 13:35 ET
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $51 Price Target
BenzingaSep 22, 2023 10:54 ET
No Data
No Data